TD Cowen raised the firm’s price target on Leidos to $166 from $155 and keeps a Buy rating on the shares. The firm said despite a VA funding delay in H2, hiked 2024 guide has opportunity thanks to Q2’s medical exam spike; a tough exam compare next year is apt to be outweighed by improvement elsewhere.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LDOS: